Moreover, the positive correlation with obesity, insulin resistance (IR) and metabolic syndrome (MetsS) has been confirmed in vivo (21), which, together with the known in vitro effects of this hepatokine, makes it reasonable to hypothesize that FGF21 may play a role in the response to weight loss interventions. The gene discussed is FGF21; the disease is Obesity.